# Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

> **NCT05253495** · PHASE2 · RECRUITING · sponsor: **New York Medical College** · enrollment: 80 (estimated)

## Conditions studied

- Non-hodgkin Lymphoma
- Hodgkin Lymphoma

## Interventions

- **DRUG:** DOC Group B
- **DRUG:** Pv-COMRAD 1 and 2 Group B
- **DRUG:** Pv-R-CYM 1 and 2 Group B
- **DRUG:** DOC Group C
- **DRUG:** MAD CPR 1 and 2
- **DRUG:** Pv-R CYVE 1 and 2
- **DRUG:** Pv-R CYVE-MTX 1 and 2
- **DRUG:** MAD CP
- **DRUG:** Pv-Cytarabine/etoposide
- **DRUG:** AD CP
- **DRUG:** Bv-AVD-R 1 and 2: COHORT IIa
- **DRUG:** Bv-NVD-R, Cycle 1-2
- **DRUG:** Bv-NVD-R, Cycle 1-4 SER
- **DRUG:** Bv-AVD-R
- **DRUG:** Bv-NVD-R, Cycle 1-4 RER
- **DRUG:** Bv-NAVD-R, Cycle 1-2
- **RADIATION:** Involved Site Radiation Therapy

## Key facts

- **NCT ID:** NCT05253495
- **Lead sponsor:** New York Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05253495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05253495, "Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05253495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*